CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-17 | Orwin John A Director | Grant or award | +4,500 | 22,375 | ||
| 2023-05-17 | Orwin John A Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | Squarer Ron Director | Grant or award | +4,500 | 22,375 | ||
| 2023-05-17 | Squarer Ron Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-17 | Bruhn Suzanne Louise Director | Grant or award | +4,500 | 15,750 | ||
| 2023-05-17 | Bruhn Suzanne Louise Director | Grant or award · Stock option (right to buy) | +13,500 | 13,500 | ||
| 2023-05-11 | Calvin Sandra SVP, Chief Accounting Officer | Sale 10b5-1 | −122 | $16.12 | $2K | 42,247 |
| 2023-05-10 | Cline Christopher R. Chief Financial Officer | Sale | −455 | $16.59 | $8K | 51,031 |
| 2023-05-10 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale 10b5-1 | −825 | $16.59 | $14K | 56,611 |
| 2023-05-10 | ROTE WILLIAM E. Senior Vice President, R&D | Sale 10b5-1 | −825 | $16.59 | $14K | 59,211 |
| 2023-05-10 | Calvin Sandra SVP, Chief Accounting Officer | Sale 10b5-1 | −436 | $16.59 | $7K | 42,369 |
| 2023-04-11 | Cline Christopher R. Chief Financial Officer | Sale | −47 | $21.49 | $1K | 51,486 |
| 2023-02-02 | Calvin Sandra SVP, Chief Accounting Officer | Sale | −360 | $22.42 | $8K | 42,805 |
| 2023-02-01 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,590 | $22.25 | $58K | 57,436 |
| 2023-02-01 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,590 | $22.25 | $58K | 60,036 |
| 2023-02-01 | Heerma Peter Chief Commercial Officer | Sale | −1,779 | $21.75 | $39K | 82,069 |
| 2023-02-01 | Cline Christopher R. Chief Financial Officer | Sale | −1,588 | $21.75 | $35K | 51,533 |
| 2023-02-01 | Dube Eric M Chief Executive Officer | Sale | −8,196 | $22.25 | $182K | 237,150 |
| 2023-02-01 | Calvin Sandra SVP, Chief Accounting Officer | Sale | −1,671 | $21.75 | $36K | 43,165 |
| 2023-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +20,250 | 60,026 |
Page 27 of 51 · 1,020 trades